Efinopegdutide
Overview
Efinopegdutide is a long-acting dual agonist of the GLP-1 and glucagon receptors, utilizing PEGylation to extend half-life and enable once-weekly dosing. The compound combines GLP-1-mediated glycemic control and appetite reduction with glucagon-driven energy expenditure and hepatic fat mobilization.
Mechanism of Action
It is under investigation for obesity and metabolic dysfunction-associated steatohepatitis..
Research Summary & Key Findings
Phase 2 trials in adults with non-alcoholic steatohepatitis (now termed metabolic dysfunction-associated steatohepatitis) have demonstrated reductions in liver fat and body weight. Results published in hepatology journals in 2021 and 2022 supported progression into later-stage development. Phase 3 trials are ongoing to assess histological endpoints and cardiovascular outcomes.
Clinical Status
Efinopegdutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
Related Peptides in Metabolic
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...
View detailsTirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...
View detailsRetatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...
View detailsAOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...
View detailsFind a Provider
Find a verified provider who offers Efinopegdutide therapy in your area.
Browse Provider MapFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Efinopegdutide.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.